Skip to main content
Erschienen in:

04.02.2023 | Original Article

Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy

verfasst von: Rajesh Rajput, Parankush Upadhyay, Siddhant Rajput, Suyasha Saini, Simmi Kharab

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Very few studies have assessed the impact of hydroxychloroquine (HCQ) on insulin resistance, beta cell function, and inflammatory markers in diabetics which takes paramount importance in understanding the mechanism of its anti-diabetic effect.

Objective

To assess the effect of hydroxychloroquine on beta cell function and insulin resistance and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin combination.

Study design and method

30 T2DM patients were inadequately controlled on glimepiride and metformin combination with an HbA1c between 7.5 and 10% (both inclusive) and were given hydroxychloroquine 400 mg in addition to glimepiride and metformin during the 12-week study period. Beta cell function, insulin resistance, high-sensitivity C-reactive protein (hsCRP), adiponectin, interleukin-6 (IL6), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and glycated hemoglobin (HbA1c) were assessed at baseline and at 12 weeks after addition of 400 mg hydroxychloroquine.

Results

With addition of HCQ, there was a significant improvement in both beta cell function and insulin resistance (p < 0.001). There was also significant improvement in FPG, PPG, and HbA1c along with significant improvement in IL6, hsCRP, and adiponectin levels post 12 weeks of adjunctive treatment with hydroxychloroquine. The changes in beta cell function and insulin resistance correlated significantly with the changes in IL6, hsCRP, and adiponectin levels.

Conclusion

Addition of hydroxychloroquine as an add-on drug in uncontrolled diabetes significantly improves the beta cell function and the insulin resistance, along with significant improvement in adiponectin, hsCRP levels, and IL6 levels.
Literatur
1.
Zurück zum Zitat Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525–31.CrossRefPubMed Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525–31.CrossRefPubMed
2.
Zurück zum Zitat Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54(7):1244–9.CrossRefPubMed Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54(7):1244–9.CrossRefPubMed
3.
Zurück zum Zitat Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30(7):1257–66.CrossRefPubMed Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30(7):1257–66.CrossRefPubMed
4.
Zurück zum Zitat Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336–43.CrossRefPubMedPubMedCentral Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336–43.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Countries. 2018;38(1):1–15. Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Countries. 2018;38(1):1–15.
6.
Zurück zum Zitat Toledo FG, Miller RG, Helbling NL, Zhang Y, Delany JP. The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: a randomized trial. Diabetes Obes Metab. 2021;23(6):1252–61.CrossRefPubMed Toledo FG, Miller RG, Helbling NL, Zhang Y, Delany JP. The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: a randomized trial. Diabetes Obes Metab. 2021;23(6):1252–61.CrossRefPubMed
7.
Zurück zum Zitat Ahmed R. Comparison between the clinical efficacy and safety of hydroxychloroquine and sitagliptin added to inadequately controlled with glimepiride and metformin in Indian patients with type 2 diabetes mellitus: a real-world observational study. EC Endocrinol Metab Res. 2018;3:147–55. Ahmed R. Comparison between the clinical efficacy and safety of hydroxychloroquine and sitagliptin added to inadequately controlled with glimepiride and metformin in Indian patients with type 2 diabetes mellitus: a real-world observational study. EC Endocrinol Metab Res. 2018;3:147–55.
8.
Zurück zum Zitat Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study. J Diabetes. 2020;12(1):91–4.CrossRefPubMed Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study. J Diabetes. 2020;12(1):91–4.CrossRefPubMed
9.
Zurück zum Zitat Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, Stecher V, Mayer L. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622–36.CrossRefPubMed Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, Stecher V, Mayer L. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622–36.CrossRefPubMed
10.
Zurück zum Zitat Yu B, Li C, Chen P, Zhou N, Wang L, Li J, Jiang H, Wang DW. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;63(10):1515–21.CrossRefPubMedPubMedCentral Yu B, Li C, Chen P, Zhou N, Wang L, Li J, Jiang H, Wang DW. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;63(10):1515–21.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Baidya A, Chakravarti HN, Saraogi RK, Gupta A, Ahmed R, Banerjee A. Efficacy of maximum and optimum doses of hydroxychloroquine added to patients with poorly controlled type 2 diabetes on stable insulin therapy along with glimepiride and metformin: association of high sensitive C-reactive protein (Hs-CRP) and glycosylated haemoglobin (HbA1c). Endocrinol Metab Syndr. 2018;7(1):2161–1017.CrossRef Baidya A, Chakravarti HN, Saraogi RK, Gupta A, Ahmed R, Banerjee A. Efficacy of maximum and optimum doses of hydroxychloroquine added to patients with poorly controlled type 2 diabetes on stable insulin therapy along with glimepiride and metformin: association of high sensitive C-reactive protein (Hs-CRP) and glycosylated haemoglobin (HbA1c). Endocrinol Metab Syndr. 2018;7(1):2161–1017.CrossRef
12.
Zurück zum Zitat Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–6.CrossRefPubMed Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–6.CrossRefPubMed
13.
Zurück zum Zitat Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83.CrossRefPubMed Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83.CrossRefPubMed
14.
Zurück zum Zitat Wakiya R, Ueeda K, Shimada H, Nakashima S, Mansour MM, Kato M, Miyagi T, Sugihara K, Ushio Y, Kameda T, Dobashi H. AB0392 the effect of hydroxychloroquine on the risk factors for atherosclerosis development. Ann Rheum Dis. 2020;79:1496. Wakiya R, Ueeda K, Shimada H, Nakashima S, Mansour MM, Kato M, Miyagi T, Sugihara K, Ushio Y, Kameda T, Dobashi H. AB0392 the effect of hydroxychloroquine on the risk factors for atherosclerosis development. Ann Rheum Dis. 2020;79:1496.
15.
Zurück zum Zitat Chakravarti HN, Nag A . Efficacy and safety of hydroxy-chloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest. 2021;44(3):481–92. Chakravarti HN, Nag A . Efficacy and safety of hydroxy-chloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest. 2021;44(3):481–92.
16.
Zurück zum Zitat Baidya A, Ahmed R. Effect of early addition of hydroxy-chloroquine in type 2 diabetic patients inadequately controlled on metformin and sulfonylurea combination therapy. Int J Res Med Sci. 2018;6:2626–32.CrossRef Baidya A, Ahmed R. Effect of early addition of hydroxy-chloroquine in type 2 diabetic patients inadequately controlled on metformin and sulfonylurea combination therapy. Int J Res Med Sci. 2018;6:2626–32.CrossRef
Metadaten
Titel
Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy
verfasst von
Rajesh Rajput
Parankush Upadhyay
Siddhant Rajput
Suyasha Saini
Simmi Kharab
Publikationsdatum
04.02.2023
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 6/2023
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-023-01173-9